专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

EP2700708B1 Enhancing the T-cell stimulatory capacity of human antigen presenting cells in vitro and in vivo and its use in vaccination 有权
公开(公告)号：EP2700708B1
公开(公告)日：2017-08-02
申请号：EP13181345.3
申请日：2013-08-22
申请人： VRIJE UNIVERSITEIT BRUSSEL
发明人： Thielemans, Kris, Maria, Magdalena , Bonehill, Aude
IPC分类号： C12N5/0784
CPC分类号： A61K39/39 , A61K39/0011 , A61K2039/5154 , A61K2039/5156 , A61K2039/5158 , A61K2039/53 , A61K2039/54 , A61K2039/55516 , A61K2039/57 , C12N5/0639 , C12N2510/00 , Y02A50/386 , Y02A50/403 , Y02A50/407 , Y02A50/484
摘要： With the current invention, we provide new methods of enhancing the T-cell stimulatory capacity of human dendritic cells (DCs) and their use in cancer vaccination. The method comprises the introduction of different molecular adjuvants to human DCs through transfection with at least two mRNA or DNA molecules encoding markers selected from the group of: CD40L, CD70, constitutively active TLR4 (caTLR4), IL-12p70, EL-selectin, CCR7 and/or 4-1 BBL; or in combination with inhibition of SOCS, A20, PD-L1 and/or STAT3 expression, for example through siRNA transfection. We could show a clear increase in the immunostimulatory capacity of DCs obtained in this way, enabling them to elicit an unexpectedly high T-cell immune response in vitro. Introduction of at least two of the above molecules, in combination with a tumor-specific antigen enables the DCs to elicit a significant host-mediated T-cell immune response in vivo against the tumor antigen and thus makes them very attractive in the manufacturing of anti-cancer vaccines.

2. 发明公开

EP3173474A1 ENHANCING THE T-CELLS STIMULATORY CAPACITY OF HUMAN ANTIGEN PRESENTING CELLS AND THEIR USE IN VACCINATION 审中-公开
标题翻译：改善与人抗原及其USE IN接种细胞的T细胞刺激能力
公开(公告)号：EP3173474A1
公开(公告)日：2017-05-31
申请号：EP16159782.8
申请日：2008-09-12
申请人： VRIJE UNIVERSITEIT BRUSSEL
发明人： Thielemans, Kris , Bonnehill, Aude
IPC分类号： C12N5/0784
CPC分类号： C12N5/0639 , C12N2501/22 , C12N2501/2307 , C12N2501/52 , C12N2501/599 , C12N2510/00 , Y02A50/386 , Y02A50/403 , Y02A50/407 , Y02A50/484
摘要： With the current invention, we provide new methods of enhancing the T-cell stimulatory capacity of human dendritic cells (DCs) and their use in cancer vaccination. The method comprises the introduction of different molecular adjuvants to human DCs through transfection with at least two mRNA or DNA molecules encoding markers selected from the group of: CD40L, CD70, constitutively active TLR4 (caTLR4), IL-12p70, EL-selectin, CCR7 and/or 4-1 BBL; or in combination with inhibition of SOCS, A20, PD-L1 and/or STAT3 expression, for example through siRNA transfection. We could show a clear increase in the immunostimulatory capacity of DCs obtained in this way, enabling them to elicit an unexpectedly high T-cell immune response in vitro. Introduction of at least two of the above molecules, in combination with a tumor-specific antigen enables the DCs to elicit a significant host-mediated T-cell immune response in vivo against the tumor antigen and thus makes them very attractive in the manufacturing of anti-cancer vaccines.
摘要翻译：与当前的发明中，我们提供增强的人树突状细胞（DC）和它们在癌症疫苗使用的T细胞刺激能力的新方法。该方法包括引入不同的分子佐剂以人DC的通过转染从以下组中选择的至少两种mRNA或编码标记物的DNA分子：CD40L，CD70，组成性活性TLR4（caTLR4），IL-12p70的，EL选择蛋白，CCR7 和/或4-1 BBL; 或与SOCS，A20，PD-L1和/或抑制STAT3的表达，例如，通过转染组合。我们可以显示出以这种方式获得DC的免疫刺激能力明显增加，使他们在体外出乎意料的高T细胞免疫反应引起。至少两个以上的分子，介绍并结合肿瘤特异性抗原启用的DCs引起在针对肿瘤抗原体内显著宿主介导的T-细胞免疫应答，从而使得它们在制造抗非常有吸引力的 -cancer疫苗。

3. 发明授权

EP1984021B1 VIABLE NON-TOXIC GRAM NEGATIVE BACTERIA 有权转让
标题翻译： LIFE资格无毒革兰氏阴性菌
公开(公告)号：EP1984021B1
公开(公告)日：2016-08-10
申请号：EP07718326.7
申请日：2007-01-19
申请人： Research Corporation Technologies, Inc
发明人： WOODARD, Ronald Wesley , MEREDITH, Timothy Charles , AGGARWAL, Parag
IPC分类号： A61K39/00 , C08B37/00 , C12N1/21
CPC分类号： C12N1/20 , A61K39/00 , A61K39/0258 , C12N1/36 , C12N15/52 , Y02A50/403 , Y02A50/407 , Y02A50/472 , Y02A50/474 , Y02A50/476 , Y02A50/478
摘要： The present invention provides non-toxic Gram-negative bacteria. In particular, the present invention provides viable Gram-negative bacteria (e.g., E. coli) substantially lacking lipopolysaccharide (LPS, endotoxin) within the outer membrane. The present invention further provides methods of generating viable non-toxic Gram-negative bacteria and uses thereof. The present invention also provides compositions and methods for inducing immune responses and for researching and developing therapeutic agents.

4. 发明公开

EP2862877A1 Methods for inhibiting atherosclerosis by administering an inhibitor of PCSK9 审中-公开
标题翻译：一种用于动脉粥样硬化的由PCSK9抑制剂的给药抑制方法
公开(公告)号：EP2862877A1
公开(公告)日：2015-04-22
申请号：EP13306436.0
申请日：2013-10-18
申请人： SANOFI
发明人： The designation of the inventor has not yet been filed
IPC分类号： C07K16/40 , A61K39/00
CPC分类号： C07K16/40 , A61K31/40 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K2317/21 , C07K2317/76 , Y02A50/407 , A61K2300/00
摘要： The present invention provides methods and compositions for inhibiting atherosclerotic plaque formation in a subject. In certain embodiments, the methods of the present invention comprise selecting a subject who has, or is at risk of developing, atherosclerosis, and administering to the subject a pharmaceutical composition comprising a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor. In certain embodiments, the PCSK9 inhibitor is an anti-PCSK9 antibody, or antigen binding protein.
摘要翻译：本发明提供了用于抑制受试者中的动脉粥样硬化斑块的形成方法和组合物。在某些实施方案中，本发明的方法包括选择谁拥有，或处于发展，动脉粥样硬化，和给予所述受试者一种药物组合物，其包括前蛋白转化酶枯草杆菌蛋白酶/可心9型（PCSK9）抑制剂的风险中的受试者。在某些实施方案中，PCSK9抑制剂是抗PCSK9抗体，或其抗原结合蛋白。

5. 发明公开

EP2829609A1 Human CTLA-4 antibodies and their uses 审中-公开
标题翻译： HumaneAntikörpergegen CTLA-4-Antikörperund Verwendungen davon
公开(公告)号：EP2829609A1
公开(公告)日：2015-01-28
申请号：EP14180954.1
申请日：2000-08-24
申请人： E. R. Squibb & Sons, L.L.C.
发明人： Korman, Alan J. , Halk, Edward L. , Lonberg, Nils , Keler, Tibor P. , Deo, Yashwant M.
IPC分类号： C12N15/13 , C07K16/28 , A61K39/395 , A01K67/027 , C12N5/10 , C12N5/20 , A61K39/00 , A61K38/19 , A61P35/00
CPC分类号： C12N15/8509 , A01K67/0276 , A01K67/0278 , A01K2207/15 , A01K2217/00 , A01K2217/05 , A01K2217/075 , A01K2227/105 , A01K2267/01 , A01K2267/0325 , A61K2039/505 , C07K16/2818 , C07K2317/21 , C07K2317/732 , C07K2319/00 , Y02A50/386 , Y02A50/403 , Y02A50/407 , Y02A50/41 , Y02A50/412 , Y02A50/466
摘要： The present invention provides novel human sequence antibodies against human CTLA-4 and methods of treating human diseases, infections and other conditions using these antibodies.
摘要翻译：本发明提供了针对人CTLA-4的新型人序列抗体以及使用这些抗体治疗人类疾病，感染和其它病症的方法。

6. 发明授权

EP2213297B8 Staphylococcus aureus antigenic polypeptides 有权
标题翻译：金黄色葡萄球菌抗原多肽
公开(公告)号：EP2213297B8
公开(公告)日：2015-01-28
申请号：EP10075018.1
申请日：2006-03-08
申请人： Absynth Biologics Limited
发明人： Foster, Simon J. , Garcia Lara, Jorge
IPC分类号： A61K39/07 , A61K39/085 , A61K39/395 , C07K7/06 , C07K14/31
CPC分类号： C07K16/1271 , A61K38/00 , A61K39/07 , A61K39/085 , A61K39/40 , C07K14/31 , C07K14/32 , C07K16/1278 , Y02A50/401 , Y02A50/407 , Y02A50/469
摘要： The invention relates to antigenic polypeptides expressed by pathogenic microbes, vaccines comprising said polypeptides; therapeutic antibodies directed to said polypeptides and methods to manufacture said polypeptides, vaccines and antibodies.

7. 发明授权

EP1860118B1 METHOD FOR PRODUCING A GLYCOPROTEIN VI - FC FUSION PROTEIN 有权转让
标题翻译： VEFAHREN用于生产的糖蛋白VI结构域含有IMMUNOADHESINE
公开(公告)号：EP1860118B1
公开(公告)日：2014-12-31
申请号：EP06023943.1
申请日：2003-06-05
申请人： advanceCor GmbH
发明人： Massberg, Steffen , Gawaz, Meinrad , Ungerer, Martin , Bültmann, Andreas , Münch, Götz , Peluso, Mario
IPC分类号： C07K19/00 , C12N15/62 , G01N33/53 , A61P7/02
CPC分类号： C07K14/745 , A61K38/00 , A61K47/6811 , A61K2039/505 , C07K14/70503 , C07K16/2803 , C07K19/00 , C07K2319/00 , C07K2319/30 , C12N2799/021 , G01N33/5088 , G01N33/86 , Y02A50/407
摘要： The invention provides use of an antibody against platelet glycoprotein VI (GPVI) for the preparation of a medicament for the prevention of intraarterial thrombosis in a patient characterized by (i) having suffered from an acute coronary or carotid syndrome and (ii)having active intraarterial lesions. Further, in vivo and in vivo screening methods for inhibitors or GP VI are provided and inhibitors identified thereby.

8. 发明公开

EP2700708A3 Enhancing the T-cell stimulatory capacity of human antigen presenting cells in vitro and in vivo and its use in vaccination 有权
标题翻译：提高体外和体内人抗原呈递细胞的T细胞刺激能力及其在疫苗接种中的应用
公开(公告)号：EP2700708A3
公开(公告)日：2014-04-16
申请号：EP13181345.3
申请日：2013-08-22
申请人： VRIJE UNIVERSITEIT BRUSSEL
发明人： Thielemans, Kris, Maria, Magdalena , Bonehill, Aude
IPC分类号： C12N5/0784
CPC分类号： A61K39/39 , A61K39/0011 , A61K2039/5154 , A61K2039/5156 , A61K2039/5158 , A61K2039/53 , A61K2039/54 , A61K2039/55516 , A61K2039/57 , C12N5/0639 , C12N2510/00 , Y02A50/386 , Y02A50/403 , Y02A50/407 , Y02A50/484
摘要： With the current invention, we provide new methods of in vitro or in vivo enhancing the T-cell stimulatory capacity of human DCs and the use thereof in cancer vaccination. The method comprises the introduction of different molecular adjuvants to human DCs by contacting or modifying them with mRNA or DNA molecule(s) encoding CD40L, and CD70 or constitutively active TLR4 (caTLR4).
摘要翻译：利用本发明，我们提供了体外或体内增强人DC的T细胞刺激能力的新方法及其在癌症疫苗接种中的用途。该方法包括通过将它们与编码CD40L和CD70或组成性活化的TLR4（caTLR4）的mRNA或DNA分子接触或修饰它们而将不同的分子佐剂引入人DC。

9. 发明公开

EP2700405A1 Herpes simplex virus (HSV) with modified tropism, uses and process of preparation thereof 有权
标题翻译：单纯疱疹病毒（HSV）mitVerändertemTropismus，Verwendungen und Verfahren zur Herstellung davon
公开(公告)号：EP2700405A1
公开(公告)日：2014-02-26
申请号：EP13168599.2
申请日：2008-05-29
申请人： Alma Mater Studiorum -Universita' di Bologna
发明人： Campadelli, Maria Gabriella , Menotti, Laura
IPC分类号： A61K35/76 , C07K14/005 , C12N7/00
CPC分类号： A61K35/763 , A61K49/04 , C07K14/005 , C07K2317/622 , C07K2319/33 , C07K2319/61 , C07K2319/74 , C12N7/00 , C12N2710/16621 , C12N2710/16622 , C12N2710/16632 , C12N2710/16633 , C12N2710/16651 , C12N2710/16722 , C12N2810/85 , Y02A50/407
摘要： A modified Herpes Simplex Virus (HSV), which has a portion of gD (glycoprotein D) of the glycoproteic envelope deleted and a heterologous single chain antibody inserted in place of such deleted portion; the modified HSV is capable of infecting cells through receptor HER2/ErbB2 but not through receptors HVEM/HveA and nectin1/HveC; uses of the modified HSV and a process of the preparation thereof are also disclosed.
摘要翻译：修饰的单纯疱疹病毒（HSV），其具有缺失的糖蛋白包膜的gD（糖蛋白D）的一部分和插入该缺失部分的异源单链抗体; 修饰的HSV能够通过受体HER2 / ErbB2感染细胞，但不能通过受体HVEM / HveA和Nectin1 / HveC感受细胞; 还公开了修饰的HSV的用途及其制备方法。

10. 发明授权

EP1749031B1 USE OF A scFv FOR DIMINISHING AN EXISTING BIOFILM 有权
标题翻译： AN的单链抗体用于减少现有生物膜USE
公开(公告)号：EP1749031B1
公开(公告)日：2013-07-17
申请号：EP05748130.1
申请日：2005-05-13
申请人： Haptogen Limited
发明人： CHARLTON, Keith , PORTER, Andrew , THORNTHWAITE, Lorna
IPC分类号： C07K16/12 , C07K16/44 , A61K39/40
CPC分类号： C07K16/44 , A61K2039/505 , C07K16/1214 , C07K2317/21 , C07K2317/622 , Y02A50/407 , Y02A50/484
摘要： The present invention provides methods of preventing or inhibiting biofilm formation by a population of bacteria, said method comprising the administration to the population of an antibody to a lactone or lactone-derived signal molecule secreted by bacteria. The invention therefore also provides methods for the treatment of bacterial infection in biofilm formation is prevented or inhibited.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式